1061358-71-1

Basic information

• Product Name: 2-[2-Chloro-5-(trifluoroMethyl)pyridin-4-ylaMino]-N-MethylbenzaMide
• Synonyms: 2-[2-Chloro-5-(trifluoroMethyl)pyridin-4-ylaMino]-N-MethylbenzaMide
• CAS NO: 1061358-71-1
• Molecular Formula: C₁₄H₁₁ClF₃N₃O
• Molecular Weight: 329.7048496
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1061358-71-1.mol

Chemical Properties

• Boiling Point: 450.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.405±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.55±0.46(Predicted)
• CAS DataBase Reference: 2-[2-Chloro-5-(trifluoroMethyl)pyridin-4-ylaMino]-N-MethylbenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-Chloro-5-(trifluoroMethyl)pyridin-4-ylaMino]-N-MethylbenzaMide(1061358-71-1)
• EPA Substance Registry System: 2-[2-Chloro-5-(trifluoroMethyl)pyridin-4-ylaMino]-N-MethylbenzaMide(1061358-71-1)

Safety Data

• Hazardous Substances Data: 1061358-71-1(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

Intermediate in the synthesis of bis(aminoaryl)pyridines.

Upstream product

• 118-48-9 isatoic anhydride 
• 4141-08-6 2-Amino-N-methylbenzamid 
• 505084-55-9 2-chloro-4-iodo-5-(trifluoromethyl)pyridine 

Downstream Products

• 1061355-48-3 N-methyl-2-{[2-{[4-(4-morpholinyl)phenyl]amino}-5-(trifluoromethyl)-4-pyridinyl]amino}benzamide 
• 1061355-43-8 N-methyl-2-{[2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyridinyl]amino}benzamide 
• 1061353-68-1 2-(2-(2-methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-N-methylbenzamide 
• 1201934-67-9 2-[[2-[(2,5-dimethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-75-9 2-[[2-[(1-isobutylpyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-69-1 2-[[2-[(1-ethyl-3-methyl-pyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-70-4 2-[[2-[(1-ethylpyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-68-0 2-[[2-[(1,5-dimethylpyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-73-7 2-[[2-[(5-cyclopropyl-2-methyl-pyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-74-8 2-[[2-[(2-ethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201933-77-8 2-[[2-[(1,3-dimethylpyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201934-72-6 2-[[2-[(1-ethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 

Relevant articles and documents

Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs

Focal adhesion kinase (FAK) is a key mediator of tumour progression and metastasis. To date, clinical trials of FAK inhibitors have reported disappointing efficacy for oncology indications. We report the design and characterisation of GSK215, a potent, selective, FAK-degrading Proteolysis Targeting Chimera (PROTAC) based on a binder for the VHL E3 ligase and the known FAK inhibitor VS-4718. X-ray crystallography revealed the molecular basis of the highly cooperative FAK-GSK215-VHL ternary complex, and GSK215 showed differentiated in-vitro pharmacology compared to VS-4718. In mice, a single dose of GSK215 induced rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels (≈96 h) and a marked PK/PD disconnect. This tool PROTAC molecule is expected to be useful for the study of FAK-degradation biology in vivo, and our results indicate that FAK degradation may be a differentiated clinical strategy versus FAK inhibition for the treatment of cancer.

DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE

Disclosed are bifunctional compounds (degraders) that target FAK or FAK and ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Two-directional approach for the rapid synthesis of 2,4-bis-aminoaryl pyridine derivatives

We have developed two different approaches in parallel to rapidly access 2,4-bis aminoaryl pyridine compounds from a common starting material. The C-4/C-2 approach uses palladium-mediated coupling reactions to sequentially functionalize C-4 and then C-2. An alternative C-2/C-4 route uses a regioselective SNAr reaction to first substitute at C-2 then subsequently at C-4 by a palladium-mediated reaction. Both approaches have been used successfully to provide a range of 2,4-bis-aminoaryl pyridine compounds.

SYNTHESIS AND USE OF KINASE INHIBITORS

An improved synthesis of a class of inhibitor of Focal Adhesion Kinase (FAK) is provided, wherein use of an expensive palladium-based catalyst is reduced and reaction yields and product purities are improved. Two key reactions of coupling of aryl halides

PYRIDINE COMPOUNDS

The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

ANILINOPYRIDINES AS INHIBITORS OF FAK

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4, Q, Z, r, and p are as defined herein. Compounds of the present invention are useful in the treatment of diseases associated with FAK overexpression, including proliferative diseases.